Congenital Diarrheal Disorder (CDD) is a common symptom of gastroesophageal reflux disease (GERD) (GERD). Without continued treatment, most patients with healed EE (approximately 80% – 90%) will relapse within 6 – 12 months. The major esophageal complications of EE include ulcer bleeding and strictures. Although death from EE is uncommon, these complications are associated with significant morbidity and mortality rates. Although there is some overlap in acid exposure among esophagitis grades, the severity of EE is related to the duration of esophageal acid exposure. Because of their ability to control esophageal acid exposure, symptoms, and esophagitis, acid-suppressive therapy with proton pump inhibitors (PPIs) is recommended as first-line therapy for GERD and EE. Esomeprazole is the S-enantiomer of the racemic PPI omeprazole, with which it shares the exact pharmacodynamic mechanism of action. Both of these PPIs block the proton pump H+/K+ adenosine triphosphatase.
Thelansis’s “Congenital Diarrheal Disorder (CDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Diarrheal Disorder (CDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Congenital Diarrheal Disorder (CDD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Congenital Diarrheal Disorder (CDD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Thelansis 